A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs PF 5230907 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Sponsors Pfizer
- 30 Jan 2017 Status changed from not yet recruiting to recruiting.
- 07 Sep 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.
- 16 Aug 2016 Planned End Date changed from 1 Oct 2018 to 1 Jun 2018.